Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Regeneron Pharmaceuticals Inc Stock Research

REGN

832.56USD+0.15(+0.02%)Market Closed
Watchlist

Market Summary

USD832.56+0.15
Market Closed
0.02%

REGN Alerts

  • 6 major insider sales recently.

REGN Stock Price

REGN RSI Chart

REGN Valuation

Market Cap

89.1B

Price/Earnings (Trailing)

20.72

Price/Sales (Trailing)

7.03

EV/EBITDA

16.63

Price/Free Cashflow

18.8

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

37.64%

Return on Equity

17.8%

Return on Assets

13.91%

Free Cashflow Yield

5.32%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

12.7B

Revenue Y/Y

10.53%

Revenue Q/Q

-0.13%

REGN Earnings

Earnings (TTM)

4.3B

Earnings Y/Y

13.65%

Earnings Q/Q

18.42%

Price Action

52 Week Range

668.00847.50
(Low)(High)

Last 7 days

0.1%

Last 30 days

0.2%

Last 90 days

17.5%

Trailing 12 Months

19.8%

REGN Financial Health

Current Ratio

5.45

REGN Investor Care

Buy Backs (1Y)

0.83%

Diluted EPS (TTM)

37.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for REGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-08
Schenkein David P
acquired
-
-
240
-
2023-09-08
Guarini Kathryn
acquired
-
-
240
-
2023-09-01
McCourt Marion
sold
-208,638
834
-250
evp commercial
2023-08-24
Van Plew Daniel P
sold
-5,216,070
841
-6,197
evp & general mgr, industrial
2023-08-23
POON CHRISTINE A
acquired
3,360,670
273
12,280
-
2023-08-23
Fenimore Christopher R.
sold (taxes)
-4,380,150
842
-5,198
svp controller
2023-08-23
Van Plew Daniel P
acquired
8,819,880
381
23,125
evp & general mgr, industrial
2023-08-23
Landry Robert E
sold
-188,212
844
-223
evp finance cfo
2023-08-23
Van Plew Daniel P
sold (taxes)
-14,264,500
842
-16,928
evp & general mgr, industrial
2023-08-23
Fenimore Christopher R.
acquired
2,797,620
399
7,000
svp controller

1–10 of 50

Which funds bought or sold REGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
added
8.68
-1,111,260
21,287,500
0.08%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
-825
5,748
-%
2023-09-20
BARCLAYS PLC
added
58.25
55,605,000
200,462,000
0.13%
2023-09-14
IMS Capital Management
unchanged
-
-28,877
201,191
0.11%
2023-09-12
Farther Finance Advisors, LLC
added
175
124,666
213,406
0.05%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
-5,569
38,802
0.05%
2023-09-01
Portside Wealth Group, LLC
new
-
285,979
285,979
0.05%
2023-08-24
Alberta Investment Management Corp
added
131
2,638,100
5,211,570
0.05%
2023-08-24
Arlington Capital Management, Inc.
sold off
-100
-227,603
-
-%
2023-08-23
Rehmann Capital Advisory Group
added
2.89
-37,067
332,684
0.03%

1–10 of 46

Latest Funds Activity

Are funds buying REGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own REGN
No. of Funds

Schedule 13G FIlings of Regeneron Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
5.9%
6,315,819
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.15%
8,722,448
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
9,166,817
SC 13G/A
Jan 11, 2023
jpmorgan chase & co
5.6%
6,101,044
SC 13G
Feb 11, 2022
capital world investors
5.1%
5,391,870
SC 13G/A
Feb 10, 2022
vanguard group inc
7.72%
8,158,515
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
9.1%
9,610,871
SC 13G/A
Feb 16, 2021
capital world investors
6.7%
7,017,122
SC 13G/A

Recent SEC filings of Regeneron Pharmaceuticals

View All Filings
Date Filed Form Type Document
Sep 27, 2023
SC 13D/A
13D - Major Acquisition
Sep 25, 2023
SC TO-T/A
SC TO-T/A
Sep 12, 2023
3
Insider Trading
Sep 12, 2023
3
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 12, 2023
SC TO-T/A
SC TO-T/A
Sep 08, 2023
8-K/A
Current Report
Sep 08, 2023
SC TO-T/A
SC TO-T/A
Sep 08, 2023
8-K
Current Report

REGN Fair Value

Loading...

Peers (Alternatives to Regeneron Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
270.6B
56.0B
3.87% 9.15%
31.15
4.83
-2.31% -31.27%
264.5B
1.8B
-4.90% 38.70%
-152.67
146.06
69.45% 14.65%
90.1B
9.5B
-0.55% 22.80%
26.79
9.48
13.83% 5.33%
89.1B
12.7B
0.20% 19.79%
20.72
7.03
-10.94% -24.40%
22.1B
1.2B
-7.72% -12.71%
-20.77
17.85
39.94% -8.44%
11.5B
1.0B
4.08% 13.95%
-12.68
11.47
20.15% -79.16%
10.9B
2.1B
2.86% 12.91%
12.51
5.17
18.01% 38.16%
MID-CAP
3.0B
225.6M
1.84% -24.74%
-5.46
13.42
-2.11% 21.02%
2.8B
-
-16.23% 132.76%
-8.48
-
- -28.88%
2.6B
402.9M
0.63% -8.39%
-3.66
6.55
20.50% -42.46%
2.4B
27.2M
10.98% -38.97%
-3.26
88.36
- -14.43%
SMALL-CAP
3.1B
-
-16.61% -39.22%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-14.36% -1.93%
11.22
4.28
77.72% 112.02%
291.7M
152.5M
-6.92% 34.57%
39.16
1.91
127.84% 103.41%
28.1M
-
-6.20% 3967.91%
-0.61
-
- -31.51%

Regeneron Pharmaceuticals News

Best Stocks
Unusual Options Trades and Bullish Sentiment Surrounding ....
Best Stocks,
8 hours ago
Investor's Business Daily
Regeneron Pharmaceuticals Stock Earns 85 RS Rating.
Investor's Business Daily,
11 hours ago
StreetInsider.com
Form 487 FT 10969.
StreetInsider.com,
13 hours ago
Investor's Business Daily
Marketscreener.com

Returns for REGN

Cumulative Returns on REGN

10.5%


10-Year Cumulative Returns

10.3%


7-Year Cumulative Returns

15.6%


5-Year Cumulative Returns

13.2%


3-Year Cumulative Returns

Risks for REGN

What is the probability of a big loss on REGN?

61.5%


Probability that Regeneron Pharmaceuticals stock will be more than 20% underwater in next one year

25.4%


Probability that Regeneron Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Regeneron Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Financials for Regeneron Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.4%12,67112,37012,17313,71014,22716,50816,07213,54312,3849,1988,4977,9387,3877,0136,5586,6226,5426,5726,7116,3656,203
Costs and Expenses5.0%8,3377,9437,4347,4787,3727,4167,1256,0695,7045,2084,9214,8524,6174,5834,3484,3704,4014,1254,1764,0103,914
  S&GA Expenses7.8%2,4432,2672,1162,0151,9311,8691,8251,5691,4511,3841,3461,4941,4721,4181,3429521,0171,0871,1271,4751,412
  R&D Expenses7.6%4,1413,8503,5933,2873,0412,9612,8602,7792,7982,8062,6472,5432,3842,5482,4501,7821,8131,4561,4692,1132,086
EBITDA-100.0%-5,0865,2606,4096,6969,4839,6698,3787,5584,7074,1033,7533,4982,7962,6702,4452,2952,7072,7302,5992,530
EBITDA Margin-100.0%-0.41*0.43*0.47*0.45*0.57*0.60*0.62*0.61*0.51*0.48*0.47*0.47*0.38*0.37*0.33*0.32*0.39*0.41*0.41*0.41*
Interest Expenses9.1%70.0064.0059.0056.0055.0056.0057.0058.0070.0065.0057.0049.0030.0029.0030.0031.0031.0029.0028.0027.0025.00
Earnings Before Taxes2.6%4,7754,6564,8596,0386,3449,1349,3268,0477,2294,3953,8103,4763,2462,5522,4292,2162,0832,5142,5542,4322,362
EBT Margin-100.0%-0.38*0.40*0.44*0.42*0.55*0.58*0.59*0.58*0.48*0.45*0.44*0.44*0.35*0.33*0.30*0.29*0.36*0.38*0.38*0.38*
Net Income2.8%4,2994,1834,3385,3705,6877,9348,0756,9966,2054,0043,5133,1562,9842,2792,1162,1442,0692,4282,4451,7981,591
Net Income Margin-100.0%-0.34*0.36*0.39*0.38*0.48*0.50*0.52*0.50*0.44*0.41*0.40*0.40*0.31*0.29*0.29*0.29*0.35*0.36*0.28*0.26*
Free Cashflow-100.0%-4,2815,0155,6688,4528,5157,0815,9402,2722,5892,6182,1752,9862,2312,4302,3712,2672,4732,1952,0331,995
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.0%30,65830,06029,21527,67827,20626,34925,43523,67221,48617,77217,16316,08414,42915,75814,80513,93913,17412,85511,73510,8069,952
  Current Assets0.1%16,92316,90915,88415,42915,53014,30614,01513,77513,33810,0559,7799,0987,8608,6447,6897,1096,6516,9296,4485,7204,815
    Cash Equivalents-50.5%1,9373,9163,1063,4913,3953,3462,8983,4322,0721,4382,1941,5731,9922,2081,6301,3851,0461,7091,4801,088918
  Inventory3.4%2,5082,4252,4022,4122,2191,9921,9512,0541,9842,1651,9171,8021,6411,4811,4161,3441,3171,2091,1511,040929
  Net PPE----3,7043,6383,5563,4823,3963,3593,2633,2223,1383,0312,9452,8902,7712,6772,6132,5762,5242,462
Liabilities1.1%6,6406,5656,5516,2396,5186,4346,6666,4146,3595,7956,1385,9595,3713,6253,7163,4353,4183,4102,9772,9372,766
  Current Liabilities0.1%3,1043,1003,1412,8793,0343,0083,9333,7153,7323,2182,6972,3383,7022,0552,0971,7651,7131,5111,4431,4171,331
    LT Debt, Non Current0.0%1,9821,9821,9811,9811,9811,9801,9801,9801,9791,9791,9791,978---------
Shareholder's Equity2.2%24,01823,49522,66421,43920,68819,91518,76917,25815,12711,97711,02510,1269,05712,13311,09010,5049,7569,4458,7577,8687,186
  Retained Earnings4.0%25,09324,12523,30722,11020,79419,94218,96816,73915,10712,00810,8939,7448,9028,0047,3806,5885,9185,7255,2544,4343,839
  Additional Paid-In Capital2.7%10,88910,5989,9499,5189,1208,7548,0887,9197,2266,8886,7166,5936,2635,2114,4294,3884,2644,1613,9123,8413,713
Shares Outstanding-0.1%107107-107108107-106105105-106110110-109109109-108108
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations10.7%4,7394,2815,0155,6688,4528,5157,0815,9402,2722,5892,6182,1752,9862,2312,4302,3712,2672,4732,1952,0331,995
  Share Based Compensation5.3%839797725681652638602535499457432444460462464458452453427428441
Cashflow From Investing-85.2%-4,288-2,315-3,784-3,939-6,570-6,031-5,384-3,677-2,014-686-70.6026.00595-1,694-2,027-2,085-2,164-1,813-1,463-1,532-1,605
Cashflow From Financing-36.7%-1,909-1,396-1,009-1,668-557-574-1,005-404-177-2,672-1,970-2,010-2,633-36.40-25211.0025.0029.00-77.10-204-216
  Buy Backs13.5%2,7612,4322,0832,5261,8031,6981,6451,1841,0945,8775,8475,7555,67460227629.0014.0014.004.004.00-

REGN Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:    
Revenues$ 3,158.1$ 2,857.2$ 6,320.2$ 5,822.3
Expenses:    
Research and development1,085.3794.32,186.51,638.1
Acquired in-process research and development0.0197.056.1225.1
Selling, general, and administrative652.0476.31,253.1926.3
Other operating (income) expense, net(0.6)(17.4)(1.1)(37.6)
Total Expenses2,141.61,747.34,357.03,453.9
Income from operations1,016.51,109.91,963.22,368.4
Other income (expense):    
Other income (expense), net85.3(133.6)14.6(317.4)
Interest expense(18.9)(13.1)(36.9)(26.7)
Total other income (expense)66.4(146.7)(22.3)(344.1)
Income before income taxes1,082.9963.21,940.92,024.3
Income tax expense114.5111.1154.7198.7
Net income$ 968.4$ 852.1$ 1,786.2$ 1,825.6
Net income per share - basic (in dollars per share)$ 9.05$ 7.90$ 16.69$ 17.01
Net income per share - diluted (in dollars per share)$ 8.50$ 7.47$ 15.68$ 16.07
Weighted average shares outstanding - basic (in shares)107.0107.9107.0107.3
Weighted average shares outstanding - diluted (in shares)113.9114.0113.9113.6
Statements of Comprehensive Income    
Net income$ 968.4$ 852.1$ 1,786.2$ 1,825.6
Other comprehensive income (loss), net of tax:    
Unrealized (loss) gain on debt securities(15.7)(53.7)41.5(198.6)
Loss on foreign currency translation(0.4)0.0(0.4)0.0
Unrealized gain on cash flow hedges0.00.00.01.0
Comprehensive income952.3798.41,827.31,628.0
Net product sales    
Revenues:    
Revenues1,772.11,754.43,440.13,393.0
Expenses:    
Cost of goods, collaboration and contract manufacturing192.4149.2400.8356.5
Collaboration revenue    
Revenues:    
Revenues1,316.71,043.62,694.82,276.1
Other revenue    
Revenues:    
Revenues69.359.2185.3153.2
Cost of collaboration and contract manufacturing    
Expenses:    
Cost of goods, collaboration and contract manufacturing$ 212.5$ 147.9$ 461.6$ 345.5

REGN Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,937.2$ 3,105.9
Marketable securities6,990.54,636.4
Accounts receivable, net5,121.35,328.7
Inventories2,507.72,401.9
Prepaid expenses and other current assets366.3411.2
Total current assets16,923.015,884.1
Marketable securities6,327.26,591.8
Property, plant, and equipment, net3,922.63,763.0
Intangible assets, net953.0915.5
Deferred tax assets2,138.51,723.7
Other noncurrent assets393.2336.4
Total assets30,657.529,214.5
Current liabilities:  
Accounts payable547.3589.2
Accrued expenses and other current liabilities2,176.02,074.2
Deferred revenue381.1477.9
Total current liabilities3,104.43,141.3
Long-term debt1,982.21,981.4
Finance lease liabilities720.0720.0
Deferred revenue116.269.8
Other noncurrent liabilities716.8638.0
Total liabilities6,639.66,550.5
Stockholders' equity:  
Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none0.00.0
Additional paid-in capital10,888.59,949.3
Retained earnings25,092.923,306.7
Accumulated other comprehensive loss(197.7)(238.8)
Treasury Stock, at cost; 24.5 shares in 2023 and 22.6 shares in 2022(11,765.9)(10,353.3)
Total stockholders' equity24,017.922,664.0
Total liabilities and stockholders' equity30,657.529,214.5
Class A Stock  
Stockholders' equity:  
Common stock0.00.0
Common Stock  
Stockholders' equity:  
Common stock$ 0.1$ 0.1
Leonard S. Schleifer
10400
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.